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cardioverter-deﬁbrillator in a patient with preexisting
Hemodialysis Reliable Outﬂow graft
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Miami, Florida.Introduction
Central vein stenosis is a well-documented consequence of
cardiovascular implantable electronic devices. In hemodial-
ysis patients, where preserving venous real estate is crucial,
use of subcutaneous implantable cardioverter-deﬁbrillators
(S-ICDs) remains controversial. We present a novel
approach for implanting an S-ICD in a patient with end-
stage renal disease, central venous stenosis, and precordial
hemodialysis graft obstructing the normal subcutaneous
implant site.Case report
History
A 34-year-old woman with end-stage renal disease secon-
dary to lupus nephritis, nonischemic cardiomyopathy, cen-
tral venous stenosis, and a Hemodialysis Reliable Outﬂow
(HeRO) graft (Merit Medical Systems, South Jordan, UT)
was referred to our center for implantation of an automatic
implantable cardioverter-deﬁbrillator (AICD). The patient
had a documented episode of sustained ventricular tachy-
cardia 6 months prior to referral, which took place in the
setting of methicillin-resistant Staphylococcus aureus bac-
teremia and required external deﬁbrillation. At that time,
transthoracic echocardiography was performed and revealed
a left ventricular ejection fraction of 25%, whereas previous
studies had been normal. Upon resolution of the infec-
tion, and placement of a HeRO graft, the patient received
optimal medical therapy for new-onset heart failure with
reduced ejection fraction and was advised to wear a LifeVest
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and the patient was scheduled to undergo implantation of an
AICD for primary prevention of sudden cardiac death.
Venograms performed prior to referral reported bilateral
subclavian vein occlusion and stenosis of the superior vena
cava. Owing to this documented stenosis and the presence of
a HeRO graft extending from right brachial artery to left
internal jugular vein and then into the right atrium (Figure 1),
traditional AICD implantation techniques were of limited
value. The decision was made to place a Boston Scientiﬁc
Emblem S-ICD in the substernal position.
The placement resulted in excellent sensing from all 3
vectors, showing neither T waves nor artiﬁcial potentials
(Figure 2). Deﬁbrillation thresholds were tested by inducing
ventricular ﬁbrillation, and the ﬁrst 70-joule shock effec-
tively terminated the arrhythmia 2 times. The shock impe-
dance was recorded as 68 ohms. There were no
complications from the case and the patient was doing well
at 2-month follow-up.Methods
After obtaining informed consent, a 4-cm subxiphoid inci-
sion was made to access the retrosternal space. Blunt
dissection was accomplished using a 10-mm cherry dissec-
tor. Under ﬂuoroscopic guidance, an S-ICD was placed
through an 11 French ultra-sheath. The lead was positioned
deep to the left sternal border and then secured in the
subxiphoid fascia using the sleeve provided by the manu-
facturer (Boston Scientiﬁc, Marlborough, MA). The lead was
then tunneled to the axillary position and connected to the
generator, which was then secured to the fascia (Figure 3).1,2Discussion
Although the literature is sparse, alternative lead positions
for S-ICDs have been supported by image-based modeling
and a limited number of case reports.3–5 Our experience
reinforces the notion that substernal lead placement, in
particular, is readily achievable and beneﬁcial in complex
scenarios.pen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2016.05.006
KEY TEACHING POINTS
 Alternative placement of subcutaneous
implantable cardioverter-deﬁbrillator (S-ICD) leads
may help avoid damage to existing devices.
 Fluoroscopy can be a helpful addition to the S-ICD
implantation procedure in difﬁcult cases.
 For patients undergoing hemodialysis, S-ICDs may
offer an effective strategy for preserving venous
real estate.
413Boyle et al Substernal Placement of a Subcutaneous ICDEntirely subcutaneous ICDs are especially useful in
patients with advanced kidney disease because of their
susceptibility to central venous stenosis and relatively high
risk of sudden cardiac death.6 However, implanting an S-
ICD in this patient as normally indicated was presumed to
carry a high risk of damage to either the lead or the
preexisting graft. Standard lead placement is in the subcuta-
neous tissue along the left sternal border.1 The metallic
portion of the dialysis graft occupied that space in thisFigure 1 Preoperative 3-dimensional computed tomography reconstruction show
lateral views are shown. The arterial graft component originates out of frame from t
venous outﬂow portion can be seen traversing superﬁcially to the body of the ster
jugular vein (c). The graft terminates in the right atrium after entering the heart th
Figure 2 Postimplant sensing from the subcutaneous implantable cardioverter-d
and alternate (25 mm/sec, 2.5 mm/mV).patient, posing a great risk for damage to either device during
implantation or during hemodialysis, when the conduit may
pulsate. If the lead and the graft were spared from damage
during traditional implant, it was theorized that oversensing
or “chatter”might occur owing to the metallic skeleton of the
HeRO graft. As demonstrated by a limited number of cases
where abandoned electrodes cause interference with new
devices, nearby metal need not be carrying current to
interfere with new ICD leads.7,8 As a result, placement in
the substernal location was warranted.Conclusion
In patients with central vein stenosis, an entirely subcuta-
neous ICD is an appealing and efﬁcacious treatment
option.1,9 This case demonstrates how the unique capabilities
of the technology can be leveraged to avoid damage to
existing implanted devices. In addition, it highlights some of
the reasons why S-ICDs are of particular value in the
hemodialysis patient population. Evidence is accumulating
for the safety and efﬁcacy of S-ICDs in patients with renaling prior Hemodialysis Reliable Outﬂow graft placement. Anterior and left-
he right brachial artery and crosses the chest subcutaneously (a). The metallic
num (b). The graft courses above the left clavicle and enters the left internal
rough the superior vena cava (d).
eﬁbrillator showing excellent readings in all 3 vectors: primary, secondary,
Figure 3 Postoperative chest radiograph showing ﬁnal placement of
subcutaneous implantable cardioverter-deﬁbrillator.
Heart Rhythm Case Reports, Vol 2, No 5, September 2016414failure who are undergoing hemodialysis, but more is still
needed.10,11
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